SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clearmind Medicine Stock Slides Friday: What's Happening?

Clearmind Medicine shares are trading lower Friday as investors weigh the biotech's move to acquire a majority stake in an EV charging firm.read more...

Clearmind Medicine To Acquire 51% Stake In Charging Robotics For $2.5 Million

(RTTNews) - Biotech company Clearmind Medicine, Inc. (CMND) announced Friday that it has entered into a definitive agreement to acquire a 51% stake in Charging Robotics, an intelligent EV wireless charging solutions provider...

Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial

Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.read more...

Clearmind Expands Its Addiction Therapy Playbook, as MEAI Could Open a New Path in Alcohol Use Disorder Treatment

Clearmind Medicine (NASDAQ:CMND) is advancing its lead therapeutic candidate, MEAI (5-Methoxy-2-aminoindane), with a successful formulation feasibility study supporting intranasal delivery as a potential additional route of administration. While still in development, the milestone reflects the company's broader strategy of enhancing the flexibility and commercial potential of its non-hallucinogenic neuroplastogen platform for treating alcohol use disorder (AUD), an area with substantial unmet medical need.

Biotech Stocks Are Loading Up on Major 2026 Catalysts and Wall Street Is Watching

Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND

 Why Did CMND Stock Jump 40% Today?

Equity

Clearmind Medicine announced that it filed a patent in Japan for its proprietary non-hallucinogenic psychedelic-based therapy for depression.

Why Is Clearmind Medicine Stock Sliding On Wednesday?

Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. Read more on the impact of CMND-100 trial results and new executive orders.read more...

US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results

US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.read more...

CMND Stock Set For Biggest Intraday Gains In Over Three Years  — Here’s Why Retail Is Eyeing Further Upside

Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.


Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Clearmind Medicine Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Clearmind said the patent covers formulations built around its proprietary MEAI formulation, which is also being used to develop treatments for weight loss and alcohol use disorder.</li><li>Earlier this week, the firm received approval from the Johns Hopkins Medicine Institutional Review Board for its trial to treat alcohol use disorder.</li><li>Clearmind had implemented a 1-for-10 reverse stock split earlier this month to meet Nasdaq’s minimum bid price requirement.</li></ul>Clearmind Medicine (CMND) lit up the biotech space on Friday, with shares soaring around 40% after the company announced a patent filing in Japan for a non-hallucinogenic psychedelic-based therapy for depression.<a href="https://stocktwits.com/symbol/CMND">CMND shares</a> recorded their biggest single-day gains since the company implemented a 1-for-10 reverse share split earlier this month to meet Nasdaq’s minimum bid price requirement of $1.<h2 class="st-heading-2">Patent To Boost CMND’s Lead Therapy Pipeline</h2>Clearmind said the patent covers formulations built around its proprietary molecule 5-Methoxy-2-aminoindan, or MEAI. The compound is Clearmind’s lead non-hallucinogenic therapy candidate, which is being developed as a safer and more accessible alternative to conventional antidepressants as well as psychedelic-based treatments.The biotech firm is continuing to expand its MEAI-based drug pipeline, with research focused on alcohol use disorder, weight loss, and other mental health conditions.<h2 class="st-heading-2">Alcohol Use Disorder Treatment Gets Thumbs Up From Johns Hopkins</h2>Earlier this week, Clearmind also received approval from the Johns Hopkins Medicine Institutional Review Board for its ongoing Phase I/II clinical trial of CMND-100. The drug is an MEAI-based oral candidate for the treatment of alcohol use disorder (AUD).The trial showed that CMND-100 remained safe and well-tolerated, even at the highest doses. No serious side effects were reported in the third patient group, and the safety results were consistent with earlier stages of the study.Clearmind has been on the investors’ radar since President Donald Trump signed an executive order last month to speed up the development and review of psychedelic-based therapies, including PTSD treatments such as Ibogaine, which the company is developing with SciSparc.<h2 class="st-heading-2">Retail Flags Bullish Technical Signal</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes were ‘extremely high.One user highlighted a bullish technical formation that could take the stock past $10.<stembedurl>https://stocktwits.com/only1mc/message/654762819</stembedurl>The company has around one million outstanding shares, according to Koyfin data.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-surge-bla-agreement-fda-melanoma-drug/cZgSpMJReMf">REPL Stock Shot Up 80% Today – What’s The Deal With FDA?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.  (Source: Getty Images)

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.22
Prev Close	$5.85
Open	$5.83
Dividend Yield	0.00%
50-Day Moving Average	$8.24
Beta	0.61
Avg. Volume	136,311.19
PE Ratio	-0.01

52-Week High	$2,688.00
52-Week Low	$5.25
Market Capitalization	$2.97M
EPS (Annual)	-$2,427.81
Price to Book	0.12
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

CMND Fundamentals